Can pregnant women take rubitidine

Introduction: Lurbinectedin, as an innovative anti-tumor drug, has demonstrated unique efficacy and potential in the field of tumor treatment. For the special group of pregnant women, the safety of medication has attracted much attention. Based on available research data and drug properties, the use of rupitidine in pregnant women is strictly limited.

Reason for contraindication in pregnant women

Embryotoxicity: Animal experimental data show that has significant toxic effects on embryos. During the organogenesis period, intravenous injection of a single dose of rupitidine (approximately 0.2 times the clinical dose) into pregnant rats can lead to an embryonic lethality rate of up to 100%. This finding strongly suggests that taking rupitidine by pregnant women may cause serious harm to the fetus and even lead to miscarriage or malformation.

Drug Recommendations: In view of the embryotoxicity of rubidine, pregnant women should strictly avoid using this drug. In order to ensure the complete elimination of the drug from the body and avoid potential risks, it is recommended that female patients take effective contraceptive measures during treatment with rubidine and within 6 months after the last dose. Male patients are also advised to use contraception with their female partners of reproductive potential during treatment and for 4 months after the last dose.

Pharmacokinetics of rubitidine:

Rubitidine undergoes a series of complex metabolic processes in the body, and its pharmacokinetic properties are of great significance in guiding clinical medication. The following is a brief introduction to the pharmacokinetics of rupitidine:

Absorption: Rubitidine is administered intravenously, so its absorption occurs primarily in the blood circulation. The drug is rapidly distributed to various tissues and organs throughout the body, reaching therapeutic concentrations.

Distribution: Rubitidine is widely distributed in the body and can penetrate the blood-brain barrier and enter the central nervous system to exert its effects. At the same time, drugs also accumulate in metabolic organs such as the liver and kidneys, and participate in subsequent metabolic processes.

Metabolism: Rubitidine is mainly metabolized by the liver. The specific metabolic pathways include oxidation, reduction, hydrolysis and other methods. Metabolites vary in activity and toxicity, and some metabolites may still have anti-tumor activity.

Excretion: Metabolized rupitidine and its products are mainly excreted through the kidneys, and some can also be excreted through the bile duct. The rate of excretion is affected by renal and hepatic function, and patients with renal or hepatic impairment may require dosage or frequency adjustment.